You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

7 Results
Guidelines and Advice
Status: Current
ID: 5-9
Version: 2
Jan 2020
Guidelines and Advice
Status: Current
ID: GL #4-4v2
Version: 2
Sep 2020
Guidelines and Advice
Status: In-Review
ID: GL END 7-3
Version: 4
Apr 2020
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Quick Link(s): Drug Monograph, Patient Info Sheet
Oct 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
riTUXimab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Drug
Other Name(s): Rituxan® SC
Quick Link(s): Drug Monograph, Patient Info Sheet
Oct 2023
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020